C-type lectin-like receptor 2: roles and drug target.
C-type lectin-like receptor-2
Cancer
Platelets
Podoplanin
Thrombosis
Journal
Thrombosis journal
ISSN: 1477-9560
Titre abrégé: Thromb J
Pays: England
ID NLM: 101170542
Informations de publication
Date de publication:
19 Mar 2024
19 Mar 2024
Historique:
received:
06
01
2024
accepted:
07
03
2024
medline:
20
3
2024
pubmed:
20
3
2024
entrez:
20
3
2024
Statut:
epublish
Résumé
C-type lectin-like receptor-2 (CLEC-2) is a member of the C-type lectin superfamily of cell surface receptors. The first confirmed endogenous and exogenous ligands of CLEC-2 are podoplanin and rhodocytin, respectively. CLEC-2 is expressed on the surface of platelets, which participates in platelet activation and aggregation by binding with its ligands. CLEC-2 and its ligands are involved in pathophysiological processes, such as atherosclerosis, cancer, inflammatory thrombus status, maintenance of vascular wall integrity, and cancer-related thrombosis. In the last 5 years, different anti- podoplanin antibody types have been developed for the treatment of cancers, such as glioblastoma and lung cancer. New tests and new diagnostics targeting CLEC-2 are also discussed. CLEC-2 mediates thrombosis in various pathological states, but CLEC-2-specific deletion does not affect normal hemostasis, which would provide a new therapeutic tool for many thromboembolic diseases. The CLEC-2-podoplanin interaction is a target for cancer treatment. CLEC-2 may be applied in clinical practice and play a therapeutic role.
Identifiants
pubmed: 38504248
doi: 10.1186/s12959-024-00594-8
pii: 10.1186/s12959-024-00594-8
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
27Subventions
Organisme : National Natural Science Foundation of China
ID : 82073935
Organisme : National Natural Science Foundation of China
ID : 82274024
Informations de copyright
© 2024. The Author(s).
Références
Colonna M, Samaridis J, Angman L. Molecular characterization of two novel C-type lectin-like receptors, one of which is selectively expressed in human dendritic cells. Eur J Immunol. 2000;30(2):697–704.
pubmed: 10671229
doi: 10.1002/1521-4141(200002)30:2<697::AID-IMMU697>3.0.CO;2-M
Suzuki-Inoue K, Fuller GL, Garcia A, Eble JA, Pohlmann S, Inoue O, et al. A novel syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood. 2006;107(2):542–9.
pubmed: 16174766
doi: 10.1182/blood-2005-05-1994
Chawaree Chaipan I, Steffen TS, Tsegaye S, Bertram I, Glowacka Y, Kato, et al. Incorporation of podoplanin into HIV released from HEK-293T cells, but not PBMC, is required for efficient binding to the attachment factor CLEC-2. Retrovirology. 2010;19(7):47.
doi: 10.1186/1742-4690-7-47
Navarro-Nunez L, Pollitt AY, Lowe K, Latif A, Nash GB, Watson SP. Platelet adhesion to podoplanin under flow is mediated by the receptor CLEC-2 and stabilised by Src/Syk-dependent platelet signalling. Thromb Haemost. 2015;113(5):1109–20.
pubmed: 25694214
pmcid: 4990172
doi: 10.1160/TH14-09-0762
Severin S, Pollitt AY, Navarro-Nunez L, Nash CA, Mourao-Sa D, Eble JA, et al. Syk-dependent phosphorylation of CLEC-2: a novel mechanism of hem-immunoreceptor tyrosine-based activation motif signaling. J Biol Chem. 2011;286(6):4107–16.
pubmed: 21098033
doi: 10.1074/jbc.M110.167502
Hughes CE, Pollitt AY, Mori J, Eble JA, Tomlinson MG, Hartwig JH, et al. CLEC-2 activates syk through dimerization. Blood. 2010;115(14):2947–55.
pubmed: 20154219
doi: 10.1182/blood-2009-08-237834
Suzuki-Inoue K, Inoue O, Ozaki Y. Novel platelet activation receptor CLEC-2: from discovery to prospects. J Thromb Haemostasis; JTH. 2011;9(Suppl 1):44–55.
pubmed: 21781241
doi: 10.1111/j.1538-7836.2011.04335.x
Izquierdo I, Barrachina MN, Hermida-Nogueira L, Casas V, Morán LA, Lacerenza S, et al. A Comprehensive Tyrosine Phosphoproteomic Analysis reveals Novel Components of the platelet CLEC-2 Signaling Cascade. Thromb Haemost. 2020;120(2):262–76.
pubmed: 31901221
doi: 10.1055/s-0039-3400295
Badolia R, Inamdar V, Manne BK, Dangelmaier C, Eble JA, Kunapuli SP. G(q) pathway regulates proximal C-type lectin-like receptor-2 (CLEC-2) signaling in platelets. J Biol Chem. 2017;292(35):14516–31.
pubmed: 28705934
pmcid: 5582844
doi: 10.1074/jbc.M117.791012
Haining EJ, Cherpokova D, Wolf K, Becker IC, Beck S, Eble JA, et al. CLEC-2 contributes to hemostasis independently of classical hemITAM signaling in mice. Blood. 2017;130(20):2224–8.
pubmed: 28835437
doi: 10.1182/blood-2017-03-771907
Kostyak JC, Mauri BR, Dangelmaier C, Patel A, Zhou Y, Eble JA, et al. TULA-2 Deficiency enhances platelet functional responses to CLEC-2 agonists. TH open: Companion J Thromb Haemostasis. 2018;2(4):e411–9.
doi: 10.1055/s-0038-1676358
Kato Y, Kaneko MK, Kunita A, Ito H, Kameyama A, Ogasawara S, et al. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci. 2008;99(1):54–61.
pubmed: 17944973
doi: 10.1111/j.1349-7006.2007.00634.x
Sobanov Y, Bernreiter A, Derdak S, Mechtcheriakova D, Schweighofer B, Düchler M, et al. A novel cluster of lectin-like receptor genes expressed in monocytic, dendritic and endothelial cells maps close to the NK receptor genes in the human NK gene complex. Eur J Immunol. 2001;31(12):3493–503.
pubmed: 11745369
doi: 10.1002/1521-4141(200112)31:12<3493::AID-IMMU3493>3.0.CO;2-9
Finney BA, Schweighoffer E, Navarro-Nunez L, Benezech C, Barone F, Hughes CE, et al. CLEC-2 and Syk in the megakaryocytic/platelet lineage are essential for development. Blood. 2012;119(7):1747–56.
pubmed: 22186994
pmcid: 3351942
doi: 10.1182/blood-2011-09-380709
Kumode T, Tanaka H, Esipinoza JL, Rai S, Taniguchi Y, Fujiwara R, et al. C-type lectin-like receptor 2 specifies a functionally distinct subpopulation within phenotypically defined hematopoietic stem cell population that contribute to emergent megakaryopoiesis. Int J Hematol. 2022;115(3):310–21.
pubmed: 35106701
doi: 10.1007/s12185-021-03220-9
Kerrigan AM, Dennehy KM, Mourao-Sa D, Faro-Trindade I, Willment JA, Taylor PR, et al. CLEC-2 is a phagocytic activation receptor expressed on murine peripheral blood neutrophils. J Immunol (Baltimore Md:1950). 2009;182(7):4150–7.
doi: 10.4049/jimmunol.0802808
Martin EM, Zuidscherwoude M, Morán LA, Di Y, García A, Watson SP. The structure of CLEC-2: mechanisms of dimerization and higher-order clustering. Platelets. 2021;32(6):733–43.
pubmed: 33819136
doi: 10.1080/09537104.2021.1906407
Watson AA, Brown J, Harlos K, Eble JA, Walter TS, O’Callaghan CA. The crystal structure and mutational binding analysis of the extracellular domain of the platelet-activating receptor CLEC-2. J Biol Chem. 2007;282(5):3165–72.
pubmed: 17132623
doi: 10.1074/jbc.M610383200
Séverin S, Pollitt AY, Navarro-Nuñez L, et al. Syk-dependent phosphorylation of CLEC-2: a novel mechanism of hem-immunoreceptor tyrosine-based activation motif signaling. J Biol Chem. 2011;286(6):4107–16.
pubmed: 21098033
doi: 10.1074/jbc.M110.167502
Hughes CE, Sinha U, Pandey A, Eble JA, O’Callaghan CA, Watson SP. Critical role for an acidic amino acid region in platelet signaling by the HemITAM (hemi-immunoreceptor tyrosine-based activation motif) containing receptor CLEC-2 (C-type lectin receptor-2). J Biol Chem. 2013;288(7):5127–35.
pubmed: 23264619
doi: 10.1074/jbc.M112.411462
Chang CH, Chung CH, Hsu CC, Huang TY, Huang TF. A novel mechanism of cytokine release in phagocytes induced by aggretin, a snake venom C-type lectin protein, through CLEC-2 ligation. J Thromb Haemostasis: JTH. 2010;8(11):2563–70.
doi: 10.1111/j.1538-7836.2010.04045.x
Manne BK, Getz TM, Hughes CE, Alshehri O, Dangelmaier C, Naik UP, et al. Fucoidan is a novel platelet agonist for the C-type lectin-like receptor 2 (CLEC-2). J Biol Chem. 2013;288(11):7717–26.
pubmed: 23341451
pmcid: 3597812
doi: 10.1074/jbc.M112.424473
Morán LA, Di Y, Sowa MA, Hermida-Nogueira L, Barrachina MN, Martin E, et al. Katacine is a new ligand of CLEC-2 that acts as a platelet agonist. Thromb Haemost. 2022;122(8):1361–8.
pubmed: 35170009
pmcid: 9393086
doi: 10.1055/a-1772-1069
Zhi Z, Jooss NJ, Sun Y, Colicchia M, Slater A, Moran LA, et al. Galectin-9 activates platelet ITAM receptors glycoprotein VI and C-type lectin-like receptor-2. J Thromb Haemostasis: JTH. 2022;20(4):936–50.
pubmed: 34936188
doi: 10.1111/jth.15625
Quintanilla M, Montero-Montero L, Renart J, Martin-Villar E. Podoplanin in inflammation and Cancer. Int J Mol Sci. 2019;20(3):707.
pubmed: 30736372
pmcid: 6386838
doi: 10.3390/ijms20030707
Herzog BH, Fu J, Wilson SJ, Hess PR, Sen A, McDaniel JM, et al. Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2. Nature. 2013;502(7469):105–9.
pubmed: 23995678
pmcid: 3791160
doi: 10.1038/nature12501
Meng D, Luo M, Liu B. The role of CLEC-2 and its ligands in Thromboinflammation. Front Immunol. 2021;12:688643.
pubmed: 34177942
pmcid: 8220156
doi: 10.3389/fimmu.2021.688643
Inoue O, Hokamura K, Shirai T, Osada M, Tsukiji N, Hatakeyama K, et al. Vascular smooth muscle cells stimulate platelets and facilitate Thrombus formation through platelet CLEC-2: implications in Atherothrombosis. PLoS ONE. 2015;10(9):e0139357.
pubmed: 26418160
pmcid: 4587843
doi: 10.1371/journal.pone.0139357
Bourne JH, Colicchia M, Di Y, Martin E, Slater A, Roumenina LT, et al. Heme induces human and mouse platelet activation through C-type-lectin-like receptor-2. Haematologica. 2021;106(2):626–9.
pubmed: 32354867
doi: 10.3324/haematol.2020.246488
Haji S, Ito T, Guenther C, Nakano M, Shimizu T, Mori D et al. Human Dectin-1 is O-glycosylated and serves as a ligand for C-type lectin receptor CLEC-2. eLife. 2022;11.
Lowe KL, Finney BA, Deppermann C, Hagerling R, Gazit SL, Frampton J, et al. Podoplanin and CLEC-2 drive cerebrovascular patterning and integrity during development. Blood. 2015;125(24):3769–77.
pubmed: 25908104
pmcid: 4463737
doi: 10.1182/blood-2014-09-603803
Osada M, Inoue O, Ding G, Shirai T, Ichise H, Hirayama K, et al. Platelet activation receptor CLEC-2 regulates blood/lymphatic vessel separation by inhibiting proliferation, migration, and tube formation of lymphatic endothelial cells. J Biol Chem. 2012;287(26):22241–52.
pubmed: 22556408
pmcid: 3381185
doi: 10.1074/jbc.M111.329987
Boulaftali Y, Hess PR, Getz TM, Cholka A, Stolla M, Mackman N, et al. Platelet ITAM signaling is critical for vascular integrity in inflammation. J Clin Investig. 2013;123(2):908–16.
pubmed: 23348738
pmcid: 3561801
Kono H, Fujii H, Suzuki-Inoue K, Inoue O, Furuya S, Hirayama K, et al. The platelet-activating receptor C-type lectin receptor-2 plays an essential role in liver regeneration after partial hepatectomy in mice. J Thromb Haemostasis: JTH. 2017;15(5):998–1008.
pubmed: 28294559
doi: 10.1111/jth.13672
Asada Y, Yamashita A, Sato Y, Hatakeyama K. Pathophysiology of atherothrombosis: mechanisms of thrombus formation on disrupted atherosclerotic plaques. Pathol Int. 2020;70(6):309–22.
pubmed: 32166823
pmcid: 7317428
doi: 10.1111/pin.12921
Shirai T, Inoue O, Tamura S, Tsukiji N, Sasaki T, Endo H, et al. C-type lectin-like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor-bearing mice. J Thromb Hemostasis: JTH. 2017;15(3):513–25.
pubmed: 28028907
doi: 10.1111/jth.13604
Gharahkhani R, Pourhadi M, Mirdamadi NS, Dana N, Rafiee L, Nedaeinia R, et al. Effect of Anti-podoplanin on malignant glioma cell viability, Invasion and Tumor Cell-Induced platelet aggregation. Arch Med Res. 2022;53(5):461–8.
pubmed: 35599058
doi: 10.1016/j.arcmed.2022.05.003
Sasano T, Gonzalez-Delgado R, Muñoz NM, Carlos-Alcade W, Cho MS, Sheth RA, et al. Podoplanin promotes tumor growth, platelet aggregation, and venous thrombosis in murine models of ovarian cancer. J Thromb Haemostasis: JTH. 2022;20(1):104–14.
pubmed: 34608736
doi: 10.1111/jth.15544
Ichikawa J, Ando T, Kawasaki T, Sasaki T, Shirai T, Tsukiji N, et al. Role of platelet C-Type lectin-like receptor 2 in promoting lung metastasis in Osteosarcoma. J bone Mineral Research: Official J Am Soc Bone Mineral Res. 2020;35(9):1738–50.
doi: 10.1002/jbmr.4045
Agrawal S, Ganguly S, Hajian P, Cao JN, Agrawal A. PDGF upregulates CLEC-2 to induce T regulatory cells. Oncotarget. 2015;6(30):28621–32.
pubmed: 26416420
pmcid: 4745681
doi: 10.18632/oncotarget.5765
Flierl U, Nero TL, Lim B, Andrews RK, Parker MW, Gardiner EE, et al. Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides: comment. J Thromb Haemostasis: JTH. 2018;16(1):181–5.
pubmed: 29052937
doi: 10.1111/jth.13877
Wang L, Yin J, Wang X, Shao M, Duan F, Wu W, et al. C-Type Lectin-Like receptor 2 suppresses AKT Signaling and Invasive activities of Gastric Cancer cells by blocking expression of phosphoinositide 3-Kinase subunits. Gastroenterology. 2016;150(5):1183–e9516.
pubmed: 26855187
doi: 10.1053/j.gastro.2016.01.034
Critelli R, Milosa F, Faillaci F, Condello R, Turola E, Marzi L, et al. Microenvironment inflammatory infiltrate drives growth speed and outcome of hepatocellular carcinoma: a prospective clinical study. Cell Death Dis. 2017;8(8):e3017.
pubmed: 28837142
pmcid: 5596578
doi: 10.1038/cddis.2017.395
Hitchcock JR, Cook CN, Bobat S, Ross EA, Flores-Langarica A, Lowe KL, et al. Inflammation drives thrombosis after Salmonella infection via CLEC-2 on platelets. J Clin Investig. 2015;125(12):4429–46.
pubmed: 26571395
pmcid: 4665792
doi: 10.1172/JCI79070
Georg F, Weber BG, Chousterman S, He AM, Fenn M, Nairz A, Anzai, et al. Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis. Science. 2015;347(6227):1260–5.
doi: 10.1126/science.aaa4268
Rayes J, Lax S, Wichaiyo S, Watson SK, Di Y, Lombard S, et al. The podoplanin-CLEC-2 axis inhibits inflammation in sepsis. Nat Commun. 2017;8(1):2239.
pubmed: 29269852
pmcid: 5740111
doi: 10.1038/s41467-017-02402-6
Xie Z, Shao B, Hoover C, McDaniel M, Song J, Jiang M et al. Monocyte upregulation of podoplanin during early sepsis induces complement inhibitor release to protect liver function. JCI Insight. 2020;5(13).
Iba T, Wada H, Levy JH. Platelet activation and thrombosis in COVID-19. Semin Thromb Hemost. 2023;49(1):55–61.
pubmed: 35738296
doi: 10.1055/s-0042-1749441
Payne H, Ponomaryov T, Watson SP, Brill A. Mice with a deficiency in CLEC-2 are protected against deep vein thrombosis. Blood. 2017;129(14):2013–20.
pubmed: 28104688
pmcid: 5408561
doi: 10.1182/blood-2016-09-742999
Wang X, Liu B, Xu M, Jiang Y, Zhou J, Yang J, et al. Blocking podoplanin inhibits platelet activation and decreases cancer-associated venous thrombosis. Thromb Res. 2021;200:72–80.
pubmed: 33548843
doi: 10.1016/j.thromres.2021.01.008
Riedl J, Preusser M, Nazari PMS, Posch F, Panzer S, Marosi C, et al. Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. Blood. 2017;129(13):1831–9.
pubmed: 28073783
doi: 10.1182/blood-2016-06-720714
Peters A, Burkett PR, Sobel RA, Buckley CD, Watson SP, Bettelli E, et al. Podoplanin negatively regulates CD4 + effector T cell responses. J Clin Investig. 2015;125(1):129–40.
pubmed: 25415436
doi: 10.1172/JCI74685
Nylander AN, Ponath GD, Axisa PP, Mubarak M, Tomayko M, Kuchroo VK, et al. Podoplanin is a negative regulator of Th17 inflammation. JCI Insight. 2017;2(17):e92321.
pubmed: 28878118
pmcid: 5621890
doi: 10.1172/jci.insight.92321
Noack M, Ndongo-Thiam N, Miossec P. Interaction among activated lymphocytes and mesenchymal cells through podoplanin is critical for a high IL-17 secretion. Arthritis Res Ther. 2016;18:148.
pubmed: 27338729
pmcid: 4917941
doi: 10.1186/s13075-016-1046-6
Kaneko MK, Abe S, Ogasawara S, Fujii Y, Yamada S, Murata T, et al. Chimeric anti-human podoplanin antibody NZ-12 of Lambda Light Chain exerts higher antibody-dependent Cellular cytotoxicity and complement-dependent cytotoxicity compared with NZ-8 of Kappa Light Chain. Monoclon Antibodies Immunodiagnosis Immunotherapy. 2017;36(1):25–9.
doi: 10.1089/mab.2016.0047
Kaneko MK, Nakamura T, Kunita A, Fukayama M, Abe S, Nishioka Y, et al. ChLpMab-23: Cancer-specific human-mouse chimeric anti-podoplanin antibody exhibits Antitumor Activity via antibody-dependent Cellular cytotoxicity. Monoclon Antibodies Immunodiagnosis Immunotherapy. 2017;36(3):104–12.
doi: 10.1089/mab.2017.0014
Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, et al. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. Cancer Med. 2017;6(4):768–77.
pubmed: 28332312
pmcid: 5387135
doi: 10.1002/cam4.1049
Kato Y, Kunita A, Fukayama M, Abe S, Nishioka Y, Uchida H, et al. Antiglycopeptide mouse monoclonal antibody LpMab-21 exerts Antitumor Activity Against Human podoplanin through antibody-dependent Cellular cytotoxicity and complement-dependent cytotoxicity. Monoclon Antibodies Immunodiagnosis Immunotherapy. 2017;36(1):20–4.
doi: 10.1089/mab.2016.0045
Yamada S, Ogasawara S, Kaneko MK, Kato Y. LpMab-23: a Cancer-specific monoclonal antibody against human podoplanin. Monoclon Antibodies Immunodiagnosis Immunotherapy. 2017;36(2):72–6.
doi: 10.1089/mab.2017.0001
Kaneko MK, Ohishi T, Nakamura T, Inoue H, Takei J, Sano M, et al. Development of Core-Fucose-Deficient Humanized and chimeric anti-human podoplanin antibodies. Monoclon Antibodies Immunodiagnosis Immunotherapy. 2020;39(5):167–74.
doi: 10.1089/mab.2020.0019
Naoya FUJITA. SEKIGUCHl Takaya, TAKAGl Satoshi. Anti-aggrus Monoclonal Antibody, Domain In Aggrus Which Is Required For Binding To CLEC-2, And Method For Screening For Aggrus-CLEC-2 Binding Inhibitor. EP3323831A1 (2018).
Takemoto A, Takagi S, Ukaji T, Gyobu N, Kakino M, Takami M, et al. Targeting Podoplanin for the Treatment of Osteosarcoma. Clin cancer Research: Official J Am Association Cancer Res. 2022;28(12):2633–45.
doi: 10.1158/1078-0432.CCR-21-4509
Kaneko MK, Oki H, Ogasawara S, Takagi M, Kato Y. Anti-podoplanin monoclonal antibody LpMab-7 detects metastatic lesions of Osteosarcoma. Monoclon Antibodies Immunodiagnosis Immunotherapy. 2015;34(3):154–61.
doi: 10.1089/mab.2014.0091
Shirai T, Inoue O, Tamura S, Tsukiji N, Sasaki T, Endo H, et al. C-type lectin-like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor-bearing mice. J Thromb Haemostasis: JTH. 2017;15(3):513–25.
pubmed: 28028907
doi: 10.1111/jth.13604
Takemoto A, Miyata K, Fujita N. Platelet-activating factor podoplanin: from discovery to drug development. Cancer Metastasis Rev. 2017;36(2):225–34.
pubmed: 28674748
pmcid: 5557876
doi: 10.1007/s10555-017-9672-2
Chang Y-W, Hsieh P-W, Chang Y-T, Lu M-H, Huang T-F, Chong K-Y, et al. Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis. Oncotarget. 2015;6(40):42733–48.
pubmed: 26528756
pmcid: 4767466
doi: 10.18632/oncotarget.5811
Tsukiji N, Osada M, Sasaki T, Shirai T, Satoh K, Inoue O, et al. Cobalt hematoporphyrin inhibits CLEC-2-podoplanin interaction, tumor metastasis, and arterial/venous thrombosis in mice. Blood Adv. 2018;2(17):2214–25.
pubmed: 30190281
pmcid: 6134222
doi: 10.1182/bloodadvances.2018016261
Xu L, Liu F, Li C, Li S, Wu H, Guo B, et al. Fucoidan suppresses the gastric cancer cell malignant phenotype and production of TGF-β1 via CLEC-2. Glycobiology. 2020;30(5):301–11.
pubmed: 31742327
doi: 10.1093/glycob/cwz097
Tseng CP, Huang YL, Chang YW, Liao HR, Chen YL, Hsieh PW. Polysaccharide-containing fraction from Artemisia argyi inhibits tumor cell-induced platelet aggregation by blocking interaction of podoplanin with C-type lectin-like receptor 2. J food drug Anal. 2020;28(1):115–23.
pubmed: 31883599
doi: 10.1016/j.jfda.2019.08.002
Chandra Manivannan A, Bargueňo MC, Devaraju V, Sen P, Pérez-Sánchez H, Mohammed Ghilan AK et al. Curcumin-Based Inhibitors of Thrombosis and Cancer Metastasis Promoting Factor CLEC 2 from Traditional Medicinal Species Curcuma longa. Evidence-based complementary and alternative medicine: eCAM. 2022;2022:9344838.
Nicolson PLR, Nock SH, Hinds J, Garcia-Quintanilla L, Smith CW, Campos J, et al. Low-dose btk inhibitors selectively block platelet activation by CLEC-2. Haematologica. 2021;106(1):208–19.
pubmed: 31949019
doi: 10.3324/haematol.2019.218545
Dangelmaier C, Vari HR, Wright M, Kostyak JC, Kunapuli SP. Clustering extent-dependent differential signaling by CLEC-2 receptors in platelets. Res Pract Thromb Haemost. 2022;6(3):e12710.
pubmed: 35573643
pmcid: 9074038
doi: 10.1002/rth2.12710
Tullemans BME, Karel MFA, Léopold V, Ten Brink MS, Baaten C, Maas SL, et al. Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function. EJHaem. 2021;2(4):685–99.
pubmed: 35845214
pmcid: 9175945
doi: 10.1002/jha2.269
Gotru SK, Chen W, Kraft P, Becker IC, Wolf K, Stritt S et al. TRPM7 kinase controls calcium responses in arterial thrombosis and stroke in mice. Arteriosclerosis, thrombosis, and vascular biology. 2018;38(2):344–52.
Wichaiyo S, Lax S, Montague SJ, Li Z, Grygielska B, Pike JA, et al. Platelet glycoprotein VI and C-type lectin-like receptor 2 deficiency accelerates wound healing by impairing vascular integrity in mice. Haematologica. 2019;104(8):1648–60.
pubmed: 30733265
pmcid: 6669159
doi: 10.3324/haematol.2018.208363
Wichaiyo S, Svasti S, Supharattanasitthi W, Morales NP. Dasatinib induces loss of vascular integrity and promotes cutaneous wound repair in mice. J Thromb Haemostasis: JTH. 2021;19(12):3154–67.
pubmed: 34402195
doi: 10.1111/jth.15499
Brown HC, Beck S, Navarro S, Di Y, Jerez EMS, Kaczmarzyk J, et al. Antibody-mediated depletion of human CLEC-2 in a novel humanized mouse model. Blood Adv. 2023;7(6):997–1000.
pubmed: 36044387
doi: 10.1182/bloodadvances.2021006463
Watanabe N, Kidokoro M, Suzuki Y, Tanaka M, Inoue S, Tsukamoto H, et al. A pull-down and slot blot-based screening system for inhibitor compounds of the podoplanin-CLEC-2 interaction. PLoS ONE. 2019;14(9):e0222331.
pubmed: 31553741
pmcid: 6760769
doi: 10.1371/journal.pone.0222331
Fei M, Xiang L, Chai X, Jin J, You T, Zhao Y, et al. Plasma soluble C-type lectin-like receptor-2 is associated with the risk of coronary artery disease. Front Med. 2020;14(1):81–90.
pubmed: 31280468
doi: 10.1007/s11684-019-0692-x
Wu X, Zhang W, Li H, You S, Shi J, Zhang C, et al. Plasma C-type lectin-like receptor 2 as a predictor of death and vascular events in patients with acute ischemic stroke. Eur J Neurol. 2019;26(10):1334–40.
pubmed: 31081579
doi: 10.1111/ene.13984
Zhang X, Zhang W, Wu X, Li H, Zhang C, Huang Z, et al. Prognostic significance of plasma CLEC-2 (C-Type lectin-like receptor 2) in patients with Acute ischemic stroke. Stroke. 2019;50:45–52.
pubmed: 30580704
doi: 10.1161/STROKEAHA.118.022563
Wada H, Ichikawa Y, Ezaki M, Yamamoto A, Tomida M, Yoshida M, et al. Elevated plasma Soluble C-Type lectin-like receptor 2 is Associated with the worsening of Coronavirus Disease 2019. J Clin Med. 2022;11(4):985.
pubmed: 35207258
pmcid: 8877880
doi: 10.3390/jcm11040985
Hideo WADA, Masahide KAWAMURA. Method for assessing risk of hemorrhagic stroke using Soluble CLEC2. WO2022255349A1 (2022).
Ishikura H, Irie Y, Kawamura M, Hoshino K, Nakamura Y, Mizunuma M, et al. Early recognition of sepsis-induced coagulopathy using the C2PAC index: a ratio of soluble type C lectin-like receptor 2 (sCLEC-2) level and platelet count. Platelets. 2022;33(6):935–44.
pubmed: 35073814
doi: 10.1080/09537104.2021.2019694
Ando K, Natsumeda M, Kawamura M, Shirakawa K, Okada M, Tsukamoto Y, et al. Elevated ratio of C-type lectin-like receptor 2 level and platelet count (C2PAC) aids in the diagnosis of post-operative venous thromboembolism in IDH-wildtype gliomas. Thromb Res. 2023;223:36–43.
pubmed: 36706720
doi: 10.1016/j.thromres.2023.01.018
Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, Yatomi Y, et al. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem. 2007;282(36):25993–6001.
pubmed: 17616532
doi: 10.1074/jbc.M702327200
Harbi MH, Smith CW, Nicolson PLR, Watson SP, Thomas MR. Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases. Platelets. 2021;32(1):29–41.
pubmed: 33307909
doi: 10.1080/09537104.2020.1849600
Damaskinaki FN, Moran LA, Garcia A, Kellam B, Watson SP. Overcoming challenges in developing small molecule inhibitors for GPVI and CLEC-2. Platelets. 2021;32(6):744–52.
pubmed: 33406951
doi: 10.1080/09537104.2020.1863939